Recently, Onyx Pharmaceuticals (ONXX) came out with positive data from a phase IIb study of carfilzomib at the 51st annual meeting of the American Society of Hematology (ASH) in New Orleans. We are pleased to see that carfilzomib was found to be well-tolerated in heavily pre-treated relapsed and refractory multiple myeloma patients. The company also stated that enrollment of 269 patients in this trial has been completed and data should be available in the second half of 2010. We believe favorable data could support a potential new drug application (NDA) filing by year-end 2010.

Additionally, Onyx reported safety data from another study that showed carfilzomib can be used in patients over a long period of time even for those who are suffering from other illnesses. Carfilzomib was added to Onyx’s portfolio following the company’s acquisition of Proteolix for an upfront cash payment of $276 million during the third quarter of

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday October 30, 2009

DrStockPick.com Stock Report!

**************************************************************

Power3 Medical Products, Inc. (OTCBB: PWRM), a leader in neurodegenerative disease and cancer biomarkers and diagnostic tests, announces further international recognition of validity as the company’s President and CSO, Dr. Ira Goldknopf, will deliver an invited Keynote address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership of

* Berkshire Hathaway (NYSE:BRK.A), in a regulatory filing Friday, said the company had increased its holdings of Wells Fargo (NYSE:WFC), Johnson & Johnson (NYSE:JNJ) and US Bancorp (NYSE:USB) during the first quarter, and cut its stake in United Health (NYSE:UNH)

* Alcoa (NYSE:AA) shares gained 3.3% Friday after Goldman Sachs (NYSE:GS) resumed coverage of the company with a "buy" rating

* Toyota (NYSE:TM) announced a Prius hybrid face-lift, with 80,000 Japanese orders already placed. The firm expects to sell up to 400,000 units globally per year

* Takeda Pharmaceutical announced plans to purchase anti-cancer drug maker IDM Pharma (NASDAQ:IDMI) for $2.64 per share in a cash tender, which represents a 65% premium to Friday's close

* MGM Mirage (NYSE:MGM) was upgraded by JP Morgan (NYSE:JPM) to "overweight" from "neutral." JP Morgan (NYSE:JPM) also raised the price target to $11 from $9, due to improved liquidity from its capital raising and low projections from 2009-2010